3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
5
Phase 1
1
Status
Withdrawn
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Carcinoma, Ovarian Epithelial
2
Carcinoma, Non-Small-Cell Lung
2
Breast Neoplasms
2
Small Cell Lung Carcinoma
1
Rectal Neoplasms
1
Pancreatic Neoplasms
1
Neoplasms by Histologic Type
1
Neoplasms
1
Multiple Myeloma
1
Lymphoproliferative Disorders
1
Lymphoma, T-Cell, Peripheral
1
Lymphoma
1
Lymphatic Diseases
1
Lung Neoplasms
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Fallopian Tube Neoplasms
1
Colorectal Neoplasms
1
Colonic Neoplasms
1
Breast Neoplasms, Male
1
Interventions
Rituximab
63
Cyclophosphamide
57
fludarabine phosphate
40
fludarabine
37
ibrutinib
28
Lenalidomide
26
Bendamustine Hydrochloride
26
Filgrastim
20
venetoclax
19
obinutuzumab
17
Bortezomib
17
Peripheral Blood Stem Cell Transplantation
15
Etoposide
12
Biopsy
12
Tacrolimus
11
Specimen Handling
11
Melphalan
11
Interleukin-2
10
tanespimycin
9
Radiotherapy
9
Cytarabine
9
aldesleukin
8
Whole-Body Irradiation
8
Magnetic Resonance Spectroscopy
8
idelalisib
7
Vorinostat
7
Paclitaxel
7
Mycophenolic Acid
7
Ipilimumab
7
Cyclosporine
7
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
Leukemia, Lymphocytic, Chronic, B-Cell
×
denileukin diftitox
×
Clear all
NCT00224354
2012-05-21
CLONTAK
Baylor College of Medicine
Phase 1
Withdrawn